ERBB2 and breast carcinoma: Additionally, HER2 heterogeneity and tumor evolution may mean the HER2 IHC/FISH results from an initial biopsy or surgical resection specimen may not accurately reflect a patient’s current HER2-status, especially given the relatively long disease course of many patients with advanced breast cancer.